文献速递心律失常血脂与心血管预防

房颤患者生物标志物动态变化与卒中及出血风险:ENGAGE AF-TIMI 48 研究

Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.
PubMed 文献 · Eur Heart J · 2021-01-01

本研究基于 ENGAGE AF-TIMI 48 试验,对 6308 例房颤患者基线及 12 个月的高敏肌钙蛋白 T、NT-proBNP 和 GDF-15 进行系列检测。结果显示近半数患者标志物存在动态变化,hsTnT 和 NT-proBNP 升高与卒中/系统性栓塞风险增加相关,GDF-15 升高与出血风险增加相关,且重新评估 ABC 风险评分可显著改善风险分层。

要点

  • 房颤患者 12 个月内 hsTnT、NT-proBNP、GDF-15 常出现动态变化。
  • hsTnT 和 NT-proBNP 升高与卒中/系统性栓塞风险增加独立相关。
  • GDF-15 升高与出血风险增加相关,重复评估 ABC 评分可改善风险再分类。

核心结论

  • 房颤患者中相当比例存在 hsTnT、NT-proBNP 和 GDF-15 的动态变化,1 年内这些标志物升高与抗凝患者的临床结局相关。

研究设计与样本

  • ENGAGE AF-TIMI 48 是一项随机试验,纳入 CHADS2 评分≥2 的房颤患者,比较口服 Xa 因子抑制剂依度沙班;本分析为嵌套前瞻性生物标志物研究,共 6308 例患者在基线和 12 个月检测 hsTnT、NT-proBNP 和 GDF-15。

主要发现

  • 12 个月内 hsTnT 动态变化(≥2 ng/L 变化)占 46.9%,NT-proBNP 动态变化(≥200 pg/mL 变化)占 51.9%,GDF-15 动态变化(≥300 pg/mL 变化)占 45.6%。
  • 对数转换的 hsTnT 和 NT-proBNP 升高与卒中/系统性栓塞风险增加相关,校正风险比分别为 1.74(95%CI 1.36-2.23)和 1.27(95%CI 1.07-1.50)。
  • 对数转换的 GDF-15 升高与出血风险增加相关,校正风险比为 1.40(95%CI 1.02-1.92)。
  • 12 个月时重新评估 ABC-stroke 和 ABC-bleeding 风险评分较基线可显著重新分类患者,净重新分类改善分别为 0.50(95%CI 0.36-0.65)和 0.42(95%CI 0.33-0.51)。

临床怎么用

  • 对房颤抗凝患者,可考虑系列检测 hsTnT、NT-proBNP 和 GDF-15 以识别卒中/栓塞及出血高风险者。
  • 动态评估 ABC-stroke 和 ABC-bleeding 评分有助于改善风险分层,指导临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We investigated whether patients with atrial fibrillation (AF) demonstrate detectable changes in biomarkers including high-sensitivity troponin T (hsTnT), N-terminal B-type natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) over 12 months and whether such changes from baseline to 12 months are associated with the subsequent risk of stroke or systemic embolic events (S/SEE) and bleeding. METHODS AND RESULTS: ENGAGE AF-TIMI 48 was a randomized trial of the oral factor Xa inhibitor edoxaban in patients with AF and a CHADS2 score of ≥2. We performed a nested prospective biomarker study in 6308 patients, analysing hsTnT, NT-proBNP, and GDF-15 at baseline and 12 months. hsTnT was dynamic in 46.9% (≥2 ng/L change), NT-proBNP in 51.9% (≥200 pg/mL change), GDF-15 in 45.6% (≥300 pg/mL change) during 12 months. In a Cox regression model, upward changes in log2-transformed hsTnT and NT-proBNP were associated with increased risk of S/SEE [adjusted hazard ratio (adj-HR) 1.74; 95% confidence interval (CI) 1.36-2.23 and adj-HR 1.27; 95% CI 1.07-1.50, respectively] and log2-transformed GDF-15 with bleeding (adj-HR 1.40; 95% CI 1.02-1.92). Reassessment of ABC-stroke (age, prior stroke/transient ischaemic attack, hsTnT, and NT-proBNP) and ABC-bleeding (age, prior bleeding, haemoglobin, hsTnT, and GDF-15) risk scores at 12 months accurately reclassified a significant proportion of patients compared with their baseline risk [net reclassification improvement (NRI) 0.50; 95% CI 0.36-0.65; NRI 0.42; 95% CI 0.33-0.51, respectively]. CONCLUSION: Serial assessment of hsTnT, NT-proBNP, and GDF-15 revealed that a substantial proportion of patients with AF had dynamic values. Greater increases in these biomarkers measured over 1 year are associated with important clinical outcomes in anticoagulated patients with AF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Oyama K, Giugliano RP, Berg DD, et al. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2021. PMID: 33760027. doi:10.1093/eurheartj/ehab141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。